The review arrives at a moment of growing frustration in breast cancer management. Although surgery, chemotherapy, radiotherapy, endocrine therapy, and targeted agents have dramatically improved outcomes for many patients, a substantial proportion still experience recurrence and progression. One reason is that breast cancer is not a single disease. Its molecular subtypes—luminal A, luminal B, HER2-positive, and triple-negative breast cancer (TNBC)—each carry distinct biological behaviors, respond differently to the same drugs, and recur at different rates. Clinicians have long sought biomarkers that can be measured after diagnosis to guide treatment decisions in real time, and metabolites are emerging as unusually informative candidates.

The logic behind metabolomics is rooted in a fundamental feature of cancer biology. Tumor cells rewire their metabolic machinery to sustain energy production, maintain redox balance, and fuel relentless biosynthesis even under the hostile conditions of hypoxia and nutrient scarcity that characterize the tumor microenvironment. Because metabolites sit at the very end of the chain linking genes to proteins to cellular function, they offer a dynamic and sensitive readout of what a tumor is actually doing—often a more faithful snapshot of phenotype than genomic or proteomic data alone. Metabolites also participate directly in signaling, immune evasion, and epigenetic modification, meaning they are not merely passive byproducts but active participants in malignant progression.

To build their evidence map, the researchers conducted a systematic PubMed search covering studies published between 2006 and 2025, screening 445 initial hits down to 53 clinical studies involving human biological samples. Of these, 36 addressed metabolomics for monitoring therapeutic response, 9 focused on prognostic markers, and 8 examined signatures of disease progression. The studies drew on a variety of biological materials—serum most commonly, followed by plasma, tumor tissue, urine, and feces—and employed a range of analytical platforms. Liquid chromatography-mass spectrometry (LC-MS) dominated the field, with nuclear magnetic resonance (NMR) spectroscopy and gas chromatography-mass spectrometry (GC-MS) as important alternatives. Most studies (41) used untargeted approaches that survey the metabolome broadly, while 7 used targeted methods and 5 combined both strategies.

One of the review’s most striking findings is how rapidly cancer treatments themselves reshape the metabolic landscape. Within the first 24 hours of paclitaxel administration, patients show significant changes in plasma concentrations of 2-hydroxybutyrate, 3-hydroxybutyrate, pyruvate, and several amino acids involved in the TCA cycle and glycolysis. Longer courses of chemotherapy perturb sphingolipid metabolism and the biosynthesis of phenylalanine, tyrosine, and tryptophan, while adjuvant regimens alter tyrosine metabolism, lysine degradation, and branched-chain amino acid synthesis. Targeted therapies leave their own fingerprints: anti-HER2 treatment elevates plasma methionine in metastatic patients, and trastuzumab increases pantothenic acid, taurine, and L-histidine in early breast cancer. Even surgery and radiotherapy produce detectable shifts. Post-surgical plasma shows rises in sucrose—possibly reflecting prolonged physiological stress—and dodecanoic acid, an apoptosis-inducing fatty acid suggesting metabolic recovery after tumor removal. Remarkably, radiotherapy shifted several serum metabolites, including leucine, isoleucine, and lactate, toward levels observed in healthy individuals, hinting at partial metabolic normalization.

Beyond documenting these shifts, the review highlights metabolomics’ real clinical promise: predicting who will respond to neoadjuvant chemotherapy (NAC), the treatment given before surgery to shrink tumors. Achieving a pathological complete response (pCR) after NAC strongly predicts better survival, so knowing in advance who will benefit is invaluable. Here, the studies reveal subtype-specific patterns. In HER2-positive breast cancer, two independent studies found that elevated pre-treatment serum spermidine predicted good response to NAC combined with anti-HER2 agents. This polyamine likely works through antitumor immunity—intratumoral spermidine accumulation correlates with activated CD8+ T cells, and high tumor-infiltrating lymphocytes are known to predict better NAC response in this subtype.

In TNBC, the picture is more complex but equally intriguing. Poor responders showed increases in chlorokynurenine, anthranilic acid, and 3-hydroxykynurenine in pre-treatment plasma, along with elevated acetylated polyamines—pointing to altered tryptophan and polyamine metabolism, both deeply intertwined with immune regulation. Another study found that responders had decreased plasma trimethylamine N-oxide (TMAO), a gut microbiota-produced metabolite previously shown to activate endoplasmic reticulum stress kinase PERK, triggering gasdermin E-mediated pyroptosis in tumor cells and enhancing CD8+ T cell-mediated antitumor immunity. Even fecal metabolites have entered the picture: an NMR study of luminal breast cancer found that good NAC responders excreted higher levels of amino acids such as methionine, valine, alanine, and isoleucine—possibly reflecting reduced tumor demand for these building blocks as the cancer shrank. This noninvasive sampling approach also underscores the interplay between gut microbiota and chemotherapy efficacy.

Metabolomics may also forecast the dark side of treatment. The review cataloged studies linking metabolic signatures to chemotherapy-induced peripheral neuropathy, hypersensitivity reactions, cardiometabolic complications, pain, fatigue, and long-term neurologic toxicity. Histidine emerged as a recurring culprit: levels of this essential amino acid predicted the severity of paclitaxel-induced neuropathy and differed between patients who experienced doxorubicin-related hypersensitivity and those who did not. Mechanistically, histidine is converted by histidine decarboxylase into histamine, the classic mediator of allergic responses and an inflammatory neuromodulator. Aromatase inhibitor-related musculoskeletal symptoms—common in postmenopausal patients on long-term endocrine therapy—were associated with upregulated organic acids and downregulated lipid and sphingolipid pathways. Even radiotherapy-induced skin reactions showed a metabolic signature involving 13 markers, including ethanolamine and thymine, with alanine, aspartate, and glutamate metabolism most significantly altered. Such pharmacometabolomics could one day enable early intervention and dose modification before toxicity becomes debilitating.

For disease monitoring, metabolomics offers the tantalizing prospect of catching recurrence before imaging can. Patients with recurrent breast cancer exhibited significantly lower serum levels of formate, histidine, proline, choline, glutamic acid, and other metabolites compared with non-recurrent patients, with branched-chain amino acid metabolism—specifically the degradation of valine, leucine, and isoleucine—showing significant disruption. A multicenter study of preoperative serum in ER-positive early breast cancer identified a metabolite signature that independently predicted recurrence regardless of clinicopathological factors, with recurrent patients showing elevated valine, leucine, isoleucine, choline, phenylalanine, histidine, glycine, tyrosine, and lactate. The involvement of branched-chain amino acids makes biological sense: they fuel the TCA cycle for ATP production, activate mTOR signaling to drive proliferation, and valine specifically promotes cell-cycle progression through translational regulation of cyclin D2. Metabolic signatures also shift across disease stages and metastatic sites. Early-stage disease shows predominant carbohydrate metabolism, stage II features disrupted glycerophospholipid remodeling, and metastatic patients display elevated acetoacetate, ketone bodies, phenylalanine, and glutamate—the latter fueling invasion through glutathione production and the system Xc-antiporter. A 15-metabolite panel predicted brain metastasis with 96.9% accuracy.

Prognostically, the most consistent signal across studies is lactate. Elevated lactate and glycine in tumor tissue, and elevated lactate and pyruvate in serum, correlate with reduced relapse-free survival and overall survival, particularly in ER-positive patients. Lactate is far more than waste: it acidifies the tumor microenvironment to promote invasion, stimulates angiogenesis through hypoxia-related pathways, suppresses cytotoxic T cells and natural killer cells, renders tumors resistant to radiotherapy, and even regulates gene expression through lactylation, a post-translational modification that drives tumor progression. Bile acids tell a contrasting story: glycochenodeoxycholate levels were positively associated with survival and inversely correlated with tumor proliferation scores. In TNBC, elevated plasma diacetylspermine, a spermine catabolite, marked increased metastasis risk and poorer survival.

The authors are candid about the field’s obstacles. Analytical platforms differ in sensitivity and metabolite coverage, sample handling varies widely, chemotherapy regimens are often pooled in ways that obscure drug-specific effects, and definitions of response differ between studies using pCR, residual cancer burden, RECIST criteria, or survival endpoints. Small sample sizes—ranging from 8 to 699 patients—compound the problem, and confounders such as diet, comorbidities, and smoking are often unaddressed. Only a minority of studies performed subtype-specific analyses or integrated metabolomics with other omics layers. The review calls for large, multi-institutional prospective trials with standardized protocols, longitudinal sampling designs, and multi-omics integration.

Still, the trajectory is clear. Metabolomics offers something conventional biomarkers and imaging cannot: the ability to detect early biochemical perturbations that precede visible disease change, from a noninvasive blood sample, repeatedly over time. If the field can achieve the standardization the authors demand, metabolic fingerprints—especially when fused with genomic and transcriptomic data—could transform breast cancer from a disease managed by population averages into one monitored molecule by molecule, patient by patient.

Small cell lung cancer is one of the most aggressive forms of lung cancer, characterized by rapid tumor growth and early metastasis. Conventional methods of diagnosis and monitoring typically rely on invasive procedures such as biopsies, which can be uncomfortable and risky for patients. In light of these challenges, the search for reliable non-invasive biomarkers is more critical than ever. The discovery of urinary biomarkers holds promise, as urine collection is straightforward and poses minimal risk to patients.

This week’s release of the study commences with a clear indication of the study’s objectives: to evaluate urinary exosomal RAB11A, a protein involved in intracellular transport, as a diagnostic and prognostic biomarker for SCLC. Through meticulous research methodologies and rigorous experiments, the authors aimed to elucidate the potential diagnostic capabilities of this exosome-derived protein. The study stands as a testament to how research is pivoting towards liquid biopsies and highlights the therapeutic possibilities these innovations may create.

The findings from this research are both compelling and statistically significant. Researchers identified elevated levels of RAB11A in the urinary exosomes of SCLC patients compared to healthy controls. This discovery has profound implications for the early detection of SCLC, as timely identification can significantly improve patient outcomes. Traditional imaging techniques, although useful, often fail to detect early-stage tumors. In contrast, this innovative approach showcases how biomarker analysis can lead to quicker, more accurate diagnoses.

Further emphasizing the novelty of this study, one of the most striking aspects is the correlation between urinary exosomal RAB11A levels and clinical outcomes in SCLC patients. Higher levels were not solely indicative of diagnosis; they also correlated with treatment response. This presents an exciting avenue for oncologists to tailor therapies based on biomarker levels, potentially optimizing treatment plans for individual patients. Thus, the integration of RAB11A into the diagnostic repertoire could revolutionize how we approach SCLC therapy, making it more personalized and effective.

The methodology employed by the researchers adds robustness to their findings. Urinary samples were meticulously collected and processed to ensure that the exosomal content was intact and representative of the patient’s physiological state. Advanced proteomic techniques such as mass spectrometry were utilized to accurately quantify RAB11A levels. The authors took great care to utilize controlled conditions, thereby strengthening the study’s reliability and reproducibility.

Moreover, the study delves into the intricate biological mechanisms underlying RAB11A’s functionality. This protein plays a pivotal role in the transport and recycling of cellular materials, facilitating the transfer of important proteins within cells. Its overexpression in cancer cells, particularly SCLC, suggests that it may play a role in tumorigenesis and cancer progression. Understanding these mechanisms not only enhances our appreciation of RAB11A’s role in lung cancer but also lays the groundwork for future studies investigating its potential as a target for therapeutic interventions.

Data analysis revealed not just a binary outcome of the presence or absence of RAB11A in urine but also nuanced interpretations of its expression levels. This provides an avenue for risk stratification in patients – identifying which individuals may have a higher propensity for aggressive disease. Such stratification could inform clinical decision-making, enhancing both an oncologist’s and a patient’s understanding of their specific cancer prognosis.

The significance of the study extends beyond mere diagnostics. RAB11A’s status as a treatment response monitoring tool positions it as a game-changing element in the oncology space. With the rise of personalized medicine, being able to ascertain how well a patient is responding to a given therapy in real-time can have monumental repercussions. Patients who may be non-responders to current therapies could be promptly switched to alternative treatments, thus minimizing unnecessary side effects and preserving quality of life during their cancer journey.

While the findings are robust and encouraging, the authors acknowledge the limitations inherent in their study. Larger cohorts and multi-center trials are necessary to validate RAB11A’s utility as a standard biomarker. Additionally, the potential heterogeneity in exosomal content depending on various physiological or pathological states must be considered in future research. Despite these considerations, the implications of this study suggest an inevitable paradigm shift in how SCLC is approached from a diagnostic and therapeutic perspective.

Continuing with the promise of technological advancements, the integration of machine learning and artificial intelligence into biomarker discovery processes could further enhance our understanding of RAB11A’s role. By analyzing vast datasets that incorporate genomic, proteomic, and metabolomic information, researchers could identify not only biomarkers but also novel therapeutic targets. The future of cancer management will undoubtedly be heavily reliant on these innovative technologies, paving the way for a more comprehensive understanding of complex disease mechanisms.

In conclusion, the study by Wang et al. sets the stage for a transformative chapter in the landscape of small cell lung cancer diagnostics and management. As we continue to uncover the potential of urinary exosomes, the prospect of improved patient outcomes and personalized treatment paths becomes increasingly tangible. RAB11A’s emergence as a non-invasive biomarker presents a promising opportunity not merely for the field of oncology, but for the entirety of precision medicine. With continued research and validation, this could very well represent a turning point in not only the management of SCLC but potentially other malignancies as well, providing a beacon of hope for patients globally.

Through tireless research and innovation, we stand on the precipice of major breakthroughs that could redefine cancer diagnostics and treatment forever. The study published in Clin Proteom is a noteworthy reminder of the importance of exploring novel biomarkers that can lead to more effective and personalized therapeutic approaches. As we venture forward, the integration of exosomal analysis into routine clinical practice could become a standard of care, reflecting the urgent need for advancements in cancer patient management.

As we continue on this exciting journey, it becomes clear that the intersection of technology, biology, and medicine holds immense potential for the future. The continuous exploration of how such proteins can influence patient care in real-time could radically reshape our understanding of oncological outcomes and therapeutic efficacy, leading to a brighter future for those battling cancer.

Subject of Research: Non-invasive biomarkers in small cell lung cancer

Article Title: Urinary exosomal RAB11A serves as a novel non-invasive biomarker for diagnosis, treatment response monitoring, and prognosis in small cell lung cancer.

Article References:

Wang, W., Liu, N., Wang, S. et al. Urinary exosomal RAB11A serves as a novel non-invasive biomarker for diagnosis, treatment response monitoring, and prognosis in small cell lung cancer. Clin Proteom 22, 30 (2025). https://doi.org/10.1186/s12014-025-09554-4

Image Credits: AI Generated

DOI:

Keywords: Urinary exosomal RAB11A, small cell lung cancer, non-invasive biomarkers, diagnosis, treatment response, prognosis.

Gallbladder adenocarcinoma remains a formidable clinical challenge owing to its aggressive nature and late-stage diagnosis in most patients. Detecting circulating tumor cells—the rare malignant cells that detach from the primary tumor and circulate in the bloodstream—offers a minimally invasive window into tumor biology and metastatic potential. However, despite their recognized significance in various solid tumors, the understanding of CTCs’ clinical applicability in advanced gallbladder cancer had been sparse until now.

Utilizing the sophisticated CanPatrol® technique, the investigators analyzed peripheral blood samples from 36 patients diagnosed with aGA prior to any treatment intervention. This cutting-edge method enables the capture and detailed phenotypic characterization of CTCs, going beyond mere enumeration to identify mesenchymal and epithelial subtypes, which have differential implications for tumor aggressiveness and therapy resistance.

Remarkably, CTCs were detectable in 75% of the cohort before treatment, underscoring their prevalent role in advanced disease dissemination. The study further demonstrated that both the presence and quantity of CTCs at baseline strongly correlated with established clinicopathological parameters such as serum levels of the tumor marker Ca199, tumor differentiation grade, and evidence of lymphatic, vascular invasion, and distant metastasis. These associations suggest that CTC burden serves as a surrogate marker of tumor aggressiveness and metastatic capability.

From a prognostic standpoint, patients positive for CTCs prior to therapy exhibited significantly reduced overall survival (OS) and progression-free survival (PFS) compared to their CTC-negative counterparts. This finding consolidates the value of CTC detection as a powerful prognosticator in managing advanced gallbladder cancer, potentially rivaling conventional imaging and biomarker assessments.

Notably, the enumeration of mesenchymal CTCs—a subtype linked with enhanced migratory and invasive properties—was intimately tied to chemotherapy responsiveness. This insight may pave the way for real-time monitoring of therapeutic efficacy, allowing clinicians to fine-tune chemotherapeutic regimens or consider alternative treatments sooner in the treatment course.

Beyond chemotherapy, the research unveiled compelling evidence that the expression of programmed cell death ligand-1 (PD-L1) on CTCs correlates with the efficacy of immunotherapy in this patient population. Given the burgeoning interest in immune checkpoint inhibitors across various malignancies, this discovery highlights CTC profiling as a promising biomarker for patient selection and therapeutic monitoring in the immuno-oncology arena.

Cox regression analyses elucidated that pre-treatment positivity for CTCs independently predicted poorer OS and was associated with distant metastasis. Moreover, patients who did not receive chemotherapy or immunotherapy manifested considerably worse clinical outcomes when CTC-positive, reinforcing the critical role of systemic treatments in altering disease trajectory even in advanced stages.

Collectively, these findings underscore the transformative potential of integrating CTC analysis into the clinical management of advanced gallbladder adenocarcinoma. By providing a dynamic, minimally invasive molecular portrait of tumor burden and biology, monitoring CTCs could enable personalized treatment adaptations, early detection of therapeutic resistance, and improved prognostication.

The study’s methodological rigor, employing multiple statistical tools including T tests, chi-squared tests, Wilcoxon rank sum, Kruskal-Wallis analyses, and survival models like log-rank tests and Cox regression, strengthens the validity of these conclusions. The robust associations drawn between CTC metrics and patient outcomes exemplify the high clinical relevance of this research.

Importantly, the research propels the concept of liquid biopsy beyond the realm of experimental inquiry into tangible clinical utility for a patient group previously lacking reliable biomarkers. As gallbladder cancer incidence rises globally, particularly in certain high-risk regions, such innovations offer hope for improved survival through precision oncology approaches.

Future studies expanding sample sizes and incorporating serial CTC monitoring throughout treatment cycles will be critical to refine the utility of CTC phenotyping, especially in distinguishing subclonal drug-resistant populations. Moreover, integration with genomic and transcriptomic analyses of CTCs may unravel novel therapeutic targets and resistance mechanisms.

Ultimately, this landmark investigation by Liu, Yan, Zhang, and colleagues carves a path toward transforming the management paradigm of advanced gallbladder adenocarcinoma. By coupling cutting-edge CTC detection technologies with rigorous clinical correlation, it exemplifies precision medicine’s promise in tackling one of the most lethal hepatobiliary cancers.

As the oncology community embraces liquid biopsy’s potential, this study adds to a growing body of evidence that blood-based biomarkers can revolutionize cancer diagnosis, prognostication, and treatment monitoring. For patients fighting gallbladder adenocarcinoma, such advancements kindle hope for earlier intervention, tailored therapies, and ultimately, improved survival outcomes in a disease historically fraught with therapeutic challenges.

Subject of Research: Circulating tumor cells (CTCs) in advanced gallbladder adenocarcinoma and their clinical prognostic and predictive applications.

Article Title: Enumeration, classification and clinical application of circulating tumor cells in advanced gallbladder adenocarcinoma

Article References:
Liu, C., Yan, C., Zhang, W. et al. Enumeration, classification and clinical application of circulating tumor cells in advanced gallbladder adenocarcinoma. BMC Cancer 25, 724 (2025). https://doi.org/10.1186/s12885-025-14140-w

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14140-w